Anti-Human CD45 (Clone 2D1)

Human PBMC

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FC
IHC

2D1 activity is directed against human CD45.

CD45 is expressed on the surface of all nucleated hematopoietic cells and their precursors, except mature erythrocytes and platelets.

CD45 is a receptor protein tyrosine phosphatase involved in immune cell activation¹. It is a large glycoprotein (180-220 kDa) with a broad range of expression in the animal kingdom, including mammals, chicken, shark, and mosquitoes. The cytoplasmic region of CD45 is highly conserved in mammals but its extracellular region varies between species. Additionally, differential splicing leads to several CD45 isoforms which can vary in glycosylation, which in turn can affect CD45 ligand interaction and function. In T cells, isoform expression is dependent on the stage of T cell maturation, activation, and differentiation.

CD45 functions in the immunological synapse of the T cell-antigen presenting cell contact zone that is formed when T cells encounter cognate antigens presented by major histocompatibility (MHC) molecules ¹. CD45 interacts with Src kinases, in particular Lck, to mediate antigen receptor signaling in T and B cells, and is required for the development and activation of lymphocytes. CD45 also interacts with CD3ζ and CD3ε chains as well as tyrosine kinase Zap 70, DAP12, the Janus kinase family, PAG, CD22, among others. With these interactions, CD45 functions to protect the host against viral, bacterial, and fungal infections.

Certain variants of CD45 are associated with autoimmune disease and dysregulation is observed in some cancers ¹. CD45 has been explored as a target of therapeutic modulation for organ transplantation ^{1, 2} , autoimmune disease ¹, bone marrow transfusion ^{3, 4, 5, 6} as well as cancer radioimmunotherapy ^{7, 8}, including a bispecific antibody targeting CD45 and 90 Y-DOTA for therapy of myeloid leukemia ⁹.

2D1 was generated by immunizing BALB/c mice with human peripheral blood mononuclear cells ^{10, 11}. Spleen cells were fused to the P3/NSI/I-Ag4-1 myeloma line and resulting supernatants screened by an indirect I¹²⁵ labeled antiglobulin binding assay. CD45 is also known as leukocyte common antigen (LCA), lymphocyte antigen 5 (Ly-5), and T200 ¹². 2D1 is also known as anti-HLe-1 ^{10, 11}.

Galectin-1, CD2, CD3, and CD4

1 Rheinländer A, Schraven B, Bommhardt U. Immunol Lett. 196:22-32. 2018.
2 Orozco JJ, Kenoyer A, Balkin ER, et al. Blood. 127(3):352-359. 2016.
3 Ruffner KL, Martin PJ, Hussell S, et al. Cancer Res. 61(13):5126-5131. 2001.
4 Matthews DC, Badger CC, Fisher DR, et al. Cancer Res. 52(5):1228-1234. 1992.
5 Matthews DC, Martin PJ, Nourigat C, et al. Blood. 93(2):737-745. 1999.
6 Koronyo-Hamaoui M, Sheyn J, Hayden EY, et al. Brain. 143(1):336-358. 2020.
7 Orozco JJ, Balkin ER, Gooley TA, et al. PLoS One. 9(12):e113601. 2014.
8 Dawicki W, Allen KJH, Garg R, et al. Oncotarget. 11(39):3571-3581. 2020.
9 Orozco JJ, Kenoyer AL, Lin Y, et al. Mol Cancer Ther. 19(12):2575-2584. 2020.
10 Bev80 Beverley PC, Linch D, Delia D. Nature. 287(5780):332-333. 1980.
11 Beverley PCL, Linch D, Callard RE. Human Leucocyte Antigens. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K. (eds) Modern Trends in Human Leukemia IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 26. Springer, Berlin, Heidelberg. 1981.
12 https://www.uniprot.org/uniprotkb/P06800/entry
13 Wellhausen SR, Slone SP, Miller JJ. Cytometry B Clin Cytom. 72(5):423-426. 2007.
14 Nathalang O, Siriphanthong K, Petvises S, et al. Ann Lab Med. 38(4):362-366. 2018.
15 Oyer JL, Croom-Perez TJ, Dieffenthaller TA, et al. Front Immunol. 13:861681. 2022. 16 Csiba A, Whitwell HL, Moore M. Br J Cancer. 50(5):699-709. 1984.
17 Terry LA, Brown MH, Beverley PC. Immunology. 64(2):331-336. 1988.